Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 3/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2438617 | 0.76 | HTR2A (0.41) | PRCPSRD5A1HTR2AHTR2CHTR2B | |
| SCHEMBL30584392 | 0.76 | TSHR (0.42) | SRD5A1SIGMAR1 | |
| SCHEMBL5871094 | 0.72 | SIGMAR1 (0.49) | PRCPSRD5A1HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL6251671 | 0.70 | SIGMAR1 (0.50) | SRD5A1HTR2CSIGMAR1IDO1 | |
| SCHEMBL11671198 | 0.70 | SRD5A1 (0.55) | SRD5A1HTR2ASIGMAR1IDO1 | |
| Magnesium SCHEMBL31510119 | 0.68 | SRD5A1 (0.53) | SRD5A1HTR2ASIGMAR1IDO1 | |
| SCHEMBL1912706 | 0.68 | HTR2C (0.53) | PRCPHTR2AHTR2CGAAHTR2B | |
| SCHEMBL30613544 | 0.67 | HTR2C (0.46) | PRCPSRD5A1DRD1HTR2AHTR2C | |
| SCHEMBL6188502 | 0.67 | HTR2C (0.46) | PRCPSRD5A1DRD1HTR2AHTR2C | |
| SCHEMBL22260050 | 0.66 | DRD2 (0.51) | PRCPSRD5A1DRD1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2547679-B1 | 2,3 DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.6]NONANE DERIVATIVES AND THEIR USE AS ANTAGONISTS OR INVERSE AGONISTS OF THE GHRELIN RECEPTOR | PFIZER (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20140080756-A1 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5]NONANE DERIVATIVES | PFIZER INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8609680-B2 | 2,3-dihydro-1H-inden-1-yl-2,7-diazaspiro[3.5] nonane derivatives | PFIZER INC. (US) | 2013-12-17 | — | — | US | disclosed |
| EP-2547679-A1 | 2,3 DIHYDRO-1H-INDEN-1-YL- 2,7-DIAZASPIRO [3.6]NONANE DERIVATIVES AND THEIR USE AS ANTAGONISTS OR INVERSE AGONISTS OF THE GHRELIN RECEPTOR | Pfizer Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| WO-2011114271-A1 | 2,3 DIHYDRO-1H-INDEN-1-YL- 2,7-DIAZASPIRO [3.6] NONANE DERIVATIVES AND THEIR USE AS ANTAGONISTS OR INVERSE AGONISTS OF THE GHRELIN RECEPTOR | PFIZER INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| US-20110230461-A1 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5] NONANE DERIVATIVES | PFIZER INC. | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080756-A1 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5]NONANE DERIVATIVES | GIPR, GLP1R, GHSR | PRCP 2020/4885SRD5A1 963/4885DRD1 723/4885 |
| US-20110230461-A1 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5] NONANE DERIVATIVES | GIPR, GLP1R, GHSR | PRCP 2078/4885SRD5A1 947/4885DRD1 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.